{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:47:14Z","timestamp":1782773234576,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"publisher","award":["RCS2023-001"],"award-info":[{"award-number":["RCS2023-001"]}],"id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Expanded hemodialysis (HDx) using medium cut-off dialyzers has been associated with lower all-cause hospitalization rates compared to conventional high-flux hemodialysis. Reductions in hospitalization frequency represent a major driver of healthcare expenditures and may contribute to improved budget sustainability in resource-constrained healthcare systems. The objective of this study was to estimate the budget impact of adopting HDx from the perspective of the Colombian healthcare system, using real-world evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A budget impact analysis was developed according to the ISPOR guidelines using a tool built in Microsoft Excel. Clinical effectiveness inputs were derived from a multicenter cohort study (COREXH-E), including an extended dataset and a difference-in-differences analysis to estimate the effect of HDx on hospitalization rate while accounting for unobserved confounding. Cost inputs were obtained from national administrative databases, including hospitalization costs and bundled dialysis payments. The analysis adopted a one-year time horizon and a third-party payer perspective representing the Colombian healthcare system. Budget impact scenarios were evaluated, assuming HDx market uptake rates of 5%, 10%, 20%, and 50%. Deterministic and probabilistic sensitivity analyses were performed to assess parameter uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Adoption of HDx was associated with net cost savings for the Colombian healthcare system across all uptake scenarios. Under hospitalization rates observed in the real-world cohort, estimated annual savings ranged from USD 472,756 to USD 4,727,564 as HDx uptake increased from 5% to 50%. In scenarios reflecting higher hospitalization rates observed in the general Colombian hemodialysis population, annual savings ranged from USD 1,344,401 to USD 13,444,010. Cost savings were primarily driven by reductions in hospitalization frequency. Probabilistic sensitivity analysis showed that HDx was cost-saving in 97.8% of simulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests that expanded hemodialysis could result in short-term cost savings for the Colombian healthcare system by reducing hospitalization-related costs without increasing dialysis expenses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12962-026-00754-9","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:46:11Z","timestamp":1777715171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Budget impact of expanded hemodialysis versus high-flux hemodialysis using real-world evidence in Colombia"],"prefix":"10.1186","volume":"24","author":[{"given":"Mauricio","family":"Sanabria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Vesga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoover","family":"Quitian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"12","key":"754_CR1","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1590\/1806-9282.64.12.1108","volume":"64","author":"GBD Silva Junior","year":"2018","unstructured":"Silva Junior GBD, Oliveira JGRD, Oliveira MRBD, Vieira LJEDS, Dias ER. Global costs attributed to chronic kidney disease: a systematic review. Rev Assoc M\u00e9dica Bras. 2018;64(12):1108\u201316.","journal-title":"Rev Assoc M\u00e9dica Bras"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20:473\u201385.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"754_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12882-019-1527-3","volume":"20","author":"D Ashby","year":"2019","unstructured":"Ashby D, Borman N, Burton J, Corbett R, Davenport A, Farrington K, et al. Renal Association Clinical Practice Guideline on Haemodialysis. BMC Nephrol. 2019;20(1):379.","journal-title":"BMC Nephrol"},{"issue":"2","key":"754_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000514550","volume":"52","author":"JS Thurlow","year":"2021","unstructured":"Thurlow JS, Joshi M, Yan G, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52(2):98\u2013107.","journal-title":"Am J Nephrol"},{"key":"754_CR5","first-page":"293","volume":"60","author":"M Sanabria","year":"2012","unstructured":"Sanabria M, Rodr\u00edguez K, S\u00e1nchez R, Astudillo K, Camargo D, Bunch A. Frecuencia y costos de hospitalizaci\u00f3n de pacientes en di\u00e1lisis en Colombia. Rev Fac Med. 2012;60:293\u2013301.","journal-title":"Rev Fac Med"},{"issue":"5","key":"754_CR6","first-page":"443","volume":"12","author":"YH Hung","year":"2022","unstructured":"Hung YH, Lai TS, Belmouaz M, Tu YC, Lai CF, Lin SL, Chen YM. Effects of Medium Cut-Off Polyarylethersulfone and Polyvinylpyrrolidone Blend Membrane Dialyzers in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Membr (Basel). 2022;12(5):443.","journal-title":"Membr (Basel)"},{"key":"754_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000468959","volume":"190","author":"C Ronco","year":"2017","unstructured":"Ronco C, La Manna G. Expanded Hemodialysis: A New Therapy for a New Class of Membranes. Contrib Nephrol. 2017;190:124\u201333.","journal-title":"Contrib Nephrol"},{"issue":"9","key":"754_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.2215\/CJN.01210120","volume":"15","author":"DE Weiner","year":"2020","unstructured":"Weiner DE, Falzon L, Skoufos L, Bernardo A, Beck W, Xiao M, et al. Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2020;15(9):1310\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"754_CR9","first-page":"205435812110670","volume":"9","author":"M Kandi","year":"2022","unstructured":"Kandi M, Brignardello-Petersen R, Couban R, Wu C, Nesrallah G. Clinical Outcomes With Medium Cut-Off Versus High-Flux Hemodialysis Membranes: A Systematic Review and Meta-Analysis. Can J Kidney Health Dis. 2022;9:205435812110670.","journal-title":"Can J Kidney Health Dis"},{"issue":"1","key":"754_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000524644","volume":"52","author":"F Maduell","year":"2023","unstructured":"Maduell F, Broseta JJ, Rodr\u00edguez-Espinosa D, Del Risco-Zevallos J, G\u00f3mez M, Rodas LM, et al. Efficacy and Safety of the Medium Cut-Off Elisio HX Dialyzer. Blood Purif. 2023;52(1):68\u201374.","journal-title":"Blood Purif"},{"issue":"4","key":"754_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3904\/kjim.2025.049","volume":"40","author":"HJ Kim","year":"2025","unstructured":"Kim HJ, Song SH. Clinical benefits and future directions of medium cut-off membranes in hemodialysis: a comprehensive review. Korean J Intern Med. 2025;40(4):557\u201370.","journal-title":"Korean J Intern Med"},{"issue":"2","key":"754_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000513328","volume":"145","author":"RM Sanabria","year":"2021","unstructured":"Sanabria RM, Hutchison CA, Vesga JI, Ariza JG, Sanchez R, Suarez AM. Expanded Hemodialysis and Its Effects on Hospitalizations and Medication Usage: A Cohort Study. Nephron. 2021;145(2):179\u201387.","journal-title":"Nephron"},{"issue":"7","key":"754_CR13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/ckj\/sfad033","volume":"16","author":"A Garc\u00eda-Prieto","year":"2023","unstructured":"Garc\u00eda-Prieto A, de la Flor JC, Coll E, Iglesias E, Reque J, Valga F. Expanded hemodialysis: what\u2019s up. Doc? Clin Kidney J. 2023;16(7):1071\u201380.","journal-title":"Doc? Clin Kidney J"},{"issue":"1","key":"754_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12882-025-04298-7","volume":"26","author":"A Gandjour","year":"2025","unstructured":"Gandjour A, Apel C, Kendzia D, et al. Health-economic evaluation of an AI-powered decision support system for anemia management in in-center hemodialysis patients. BMC Nephrol. 2025;26(1):496.","journal-title":"BMC Nephrol"},{"issue":"3","key":"754_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/hdi.13015","volume":"26","author":"MJ Blackowicz","year":"2022","unstructured":"Blackowicz MJ, Falzon L, Beck W, Tran H, Weiner DE. Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: An evaluation of a randomized clinical trial. Hemodial Int. 2022;26(3):449\u201355.","journal-title":"Hemodial Int"},{"issue":"5","key":"754_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/1744-9987.13620","volume":"25","author":"JG Ariza","year":"2021","unstructured":"Ariza JG, Walton SM, Suarez AM, Sanabria M, Vesga JI. An initial evaluation of expanded hemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia. Ther Apher Dial. 2021;25(5):621\u20137.","journal-title":"Ther Apher Dial"},{"issue":"4","key":"754_CR17","doi-asserted-by":"publisher","first-page":"100431","DOI":"10.1016\/j.xkme.2022.100431","volume":"4","author":"AP Molano","year":"2022","unstructured":"Molano AP, Hutchison CA, Sanchez R, Rivera AS, Buitrago G, Dazzarola MP, et al. Medium Cutoff Versus High-Flux Hemodialysis Membranes and Clinical Outcomes: A Cohort Study Using Inverse Probability Treatment Weighting. Kidney Med. 2022;4(4):100431.","journal-title":"Kidney Med"},{"key":"754_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40471-023-00327-x","volume":"11","author":"S Rothbard","year":"2024","unstructured":"Rothbard S, Etheridge JC, Murray EJ. A Tutorial on applying the difference-in-differences method to health data. Curr Epidemiol Rep. 2024;11:85\u201395.","journal-title":"Curr Epidemiol Rep"},{"issue":"1","key":"754_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13561-025-00620-z","volume":"15","author":"O Espinosa","year":"2025","unstructured":"Espinosa O, Rodr\u00edguez-Lesmes P, Prada S, Bol\u00edvar M, Mej\u00eda-Becerra JD, Vecino-Ort\u00edz AI. Health insurance premium in Colombia for 2025: a strictly political-ideological decision without technical-scientific arguments? Health Econ Rev. 2025;15(1):31.","journal-title":"Health Econ Rev"},{"issue":"1","key":"754_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Principles of good practice for budget impact analysis II: report of the ISPOR Task Force on Good Research Practices \u2013 Budget Impact Analysis. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health"},{"issue":"3","key":"754_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/sdi.13257","volume":"38","author":"G Kosmadakis","year":"2025","unstructured":"Kosmadakis G, Necoara A, Baudenon J, Deville C, Enache I, Chelaru E. The Multidimensional Impact of Expanded Hemodialysis: A Comprehensive Review. Semin Dial. 2025;38(3):176\u201386.","journal-title":"Semin Dial"},{"issue":"8","key":"754_CR22","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1681\/ASN.0000000655","volume":"36","author":"JH Lim","year":"2025","unstructured":"Lim JH, Seo YJ, Jeon Y, et al. Expanded Hemodialysis with Theranova Dialyzer and Residual Kidney Function in Patients Starting Long-Term Hemodialysis: A Randomized Controlled Trial. J Am Soc Nephrol. 2025;36(8):1614\u201325.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"754_CR23","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jval.2022.09.348","volume":"25","author":"S Jung","year":"2022","unstructured":"Jung S, Yoon S, Blackowicz M. EE96 Budget-Impact Analysis of Adopting Expanded Hemodialysis (HDX) Via Theranova\u00ae in Korea. Value Health. 2022;25(12):S72.","journal-title":"Value Health"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00754-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00754-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00754-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:22:37Z","timestamp":1782771757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00754-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00754-9","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Clinical Research Ethics Committee of the Renal Therapy Services Colombia (June 29, 2023, minutes, item number 002), which exempted the study from the requirement of informed consent since the study does not contain identifiable information and is a retrospective observational study. This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"An abridged version of this data was presented as a poster at the International Society of Nephrology congress, Buenos Aires, Argentina, 2024. Kidney International Reports,","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}},{"value":"Dr. Sanabria is an employee of Renal Care Services Latin-America, Ms. Vesga is an employee of Renal Care Services Colombia. Dr Rivera is an employee of Vantive, USA. Dr Rutherford is an employee of Vantive, Switzerland. Dr Quitian is an employee Faculty of Economics of the University of the Andes, Bogota and has received honorarium for economic analysis from Baxter Healthcare Corporation. Dr Lindholm is an employee of Karolinska Institutet.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}